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Introduction
National CF NBS started in Poland in September
2006. The programme was introduced and coordinated
by the Screening Department and CF Centre in the
Institute of Mother and Child and was rolled out across
the country. Screening for CF was based on the 3 stage
IRT/DNA/IRT protocol. Infants with positive neonatal
CF screening results were called to a CF Centre for
verification. The same day two sweat tests were per-
formed: classical  Gibson-Cook and Nanoduct based
on conductivity. Thanks to quick conductivity test
results diagnosed infants could pass all the trainings
and return home on the same day [1,2].
Measurement of sweat  chloride concentration by
the quantitative pilocarpine iontophoresis test (QPIT),
as described by Gibson and Cook [3,4], is considered
to be the most accurate method  to diagnose CF and
has been accepted as the standard for sweat testing [5].
However, this method involves multiple steps for col-
lection and analysis of the sweat sample and involves
the risk of volumetric,  gravimetric, condensate and
evaporation errors in the procedure. In this context, the
measurement of sweat conductivity is an increasingly
used method because it is easier to perform and
requires  a smaller sample than QPIT [6].
Sweat contains a variety of ions which contribute
towards measurements of conductivity and osmolarity.
Conductivity represents the nonspecific measurements
of the total anion activity in a solution  and therefore
has a higher concentration  in sweat than chloride. The
reading is displayed in equivalent NaCl molarity units
(mmol/L) [7]. The determination of  conductivity in
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sweat, as a test for approximation to electrolytes in a
non selective manner, has been shown to be as effec-
tive as the quantitative determination of sweat chloride
or sodium concentration [8,9].
Sweat collected in Macroduct coils and transferred
to the Sweat-Chek conductivity analyzer (Wescor Inc.,
Logan, Utah) has been used in some settings. Recently,
a new conductivity analyzer, Nanoduct, has been devel-
oped for use especially in the neonatal population.  
Nanoduct is a new diagnostic system that induces,
collects and analyzes sweat in one step while the
required electrodes and sensors are attached to the
patient [10]. Compared to the sweat volumes between
75 to 100 µl required by other systems, this system
needs only 3 µl of sweat and the results are available
within half an hour. 
The aim of our study was to evaluate the applica-
bility of Nanoduct, a new system measuring conduc-
tivity and  giving immediate results in a CF NBS pro-
tocol. Nanoduct measurements were compared with
classic pilocarpine sweat chloride concentration as ref-
erence to assess its accuracy and precision as a diag-
nostic analytical procedure.
Materials and methods
Patients. 1057 (528 conductivity and 529 chloride concentration)
sweat tests were performed between  01.09.2006 and 01.06.2009 at
the CF Centre of the Institute of Mother and Child in Warsaw.  
487 infants aged  4-6 weeks  with positive results of screening
tests (IRT-I over 99.4 percentile and one or two CFTR mutations or
IRT-II over cut-off) were called for further  evaluation in our CF
Centre (sweat tests and specialist consultation). Control included
45 healthy infants 4-8 weeks old, who did not need a recall within
CF NBS programme (negative screening result after the first step). 
Sweat tests. In the infants two kinds of sweat tests were performed
(quantitative pilocarpine iontophoresis and conductometry). Both
tests were performed on the same day, by the same qualified per-
sonnel. Quantitative pilocarpine iontophoresis chloride was tested
according to the Gibson and Cook method [3], i.e. quantitative
analyses of sweat chloride by a manual titration using the Schales
and Schales mercuric nitrate procedure. This method is well estab-
lished as the gold standard but is time consuming and open to many
risks of error. 
In the Nanoduct system continuous flow analysis eliminates a
separate collection phase and analyzes samples within minutes [7].
The possibility of human error is significantly reduced. The system
provides automatic display of initial sweating rate and automatic
averaging of conductivity. With shorter stimulation time and smaller
sample requirement (3 microliters of sweat),  reliable results are
available in a few minutes. Nanoduct's small components fit easily
on neonates. It is an integrated diagnostic system that simplifies the
procedure for all patients.  Nanoduct incorporates the classic method
of inducing sweat by pilocarpine iontophoresis. The pilocarpine is
carried into the dermis of the patient from Pilogel® Iontophoretic
discs via a controlled electrical current supplied by the Nanoduct
Inducer/Analyzer. This is followed by continuous flow analysis of
sweat electrolyte concentration using the conductivity sensor.
DNA analysis, based mainly on the sequencing of eight CFTR
regions, covered 505 CFTR variants including the 16 most com-
mon CFTR mutations in the Polish population.
Depending on DNA and sweat tests analysis results, infants
were divided into 3 main groups: CF, non-CF  and observational
group. CF group included infants with confirmed diagnosis and
known CFTR mutations causing CF, non-CF  consisted of the fol-
lowing subgroups: control  (healthy infants with negative screen-
ing test), healthy infants from CF NBS recall (false positives) and
CFTR mutation carriers.  Observational group  consisted of infants
without established diagnosis, who needed further clinical obser-
vation, repeated sweat tests and more detailed salt transport inves-
tigations, also nasal potential difference (NPD). The observational
group consisted of 6 infants. Four of them had the same genotype:
F508del/R117H,IVS8-7T/IVS8-9T, one  R553X/ R117H,IVS8-
7T/IVS8-7T and one G542X/ R117H, IVS8-7T/IVS8-9T. 
The infants had pancreatic function assessed  clinically, based
on weight gain and stool features with laboratory confirmation by
faecal elastase-1. Depending on the results they were described as:
pancreatic sufficient (CF/PS) and pancreatic insufficient (CF/PI).
Infants from all the other groups were pancreatic sufficient.
Statistical analysis. The results of both sweat tests were assessed
statistically using descriptive measures for one variant, centiles,
mean, SD, and median. The association of both methods was
assessed through the correlation coefficient. The Mann-Whitney U
test was applied for pair wise group comparison. Limits of agree-
ment were calculated with 95% confidence intervals. The capabil-
ity of the conductivity and QPIT to discriminate between CF and
non-CF was assessed by constructing a receiver operating charac-
teristic (ROC) curve and overall accuracy of the best cut-off values
was assessed through calculation of sensitivity, specificity, positive
predictive  value (PPV), negative predictive value (NPV) and
kappa coefficient.
Results
Among 487 infants from CF NBS, in 481 cases both
sweat tests were performed. Due to technical reasons 3
infants had no Nanoduct and 3 had no iontophoresis
(not enough sweat). A summary of the tests is present-
ed in Table 1 and 2.
There were 45 CF diagnosed children, 6 staying
under observation. In the control group of 45 infants,
one child had no Nanoduct result. CF infants had a
mean conductivity of  99.8±18.8 mmol/L (mean
852±24.2  mmol/L if pancreatic sufficient-PS versus
106.1±11.7 mmol/L if pancreatic insufficient-PI) and a
mean chloride concentration of 74.0±18.4 mmol/L
(64.3±19.0 mmol/L in PS vs. 78.0±16.8 mmol/L in PI)
(Table 1 and 2). CF children who were pancreatic suf-
ficient had lower (nearer to normal range) values in
both tests versus higher values of pancreatic insuffi-
cient infants. Non-CF infants values were 29.8±7.7
and 19.2±6.6 mmol/L respectively. Similar means,
medians characterized all non-CF infants whatever
was their origin (Table 2). In  Mann-Whitney U test
p>0.02  confirmed no differences between the groups.
Nanoduct mean value +3SD in control group was 50.2
mmol/L and mean +3SD in healthy infants recalled for
sweat tests was 53.4 mmol/L. Chloride concentration
mean value +3SD was 44.1 mmol/L in control infants,
mean +3SD was 39.7 mmol/L in healthy infants origi-
nating from recalls.
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Optimal level of cut-off values were calculated
from receiver operating characteristics (ROC) (Fig. 1
and Fig. 2). Receiver operating characteristics (ROC)
curve for conductivity sweat  test (Fig. 1)  showed the
capacity to predict cystic fibrosis diagnosis based on
molecular analysis and clinical examination.  Optimal
cut off based on screened children follow up experi-
ence for the conductivity test was 50 mmol/L (no lost
CF, 11 false positive) with 100% sensitivity, 97.5%
specificity and PPV 79.25 (Table 3). No false positives
were found in values over 60 mmol/L. The conductiv-
ity values between 50 and 60 mmol/L were assumed
borderline.
Optimal cut off for chloride concentration was
established at 34 mmol/L (no lost CF, 11 false posi-
tive) with 100% sensitivity and 97.5% specificity
(Fig. 2 and Table 4). No false positives were found
in the range of values over 46 mmol/L. The chloride
levels between 34 and 46 mmol/L were assumed bor-
derline (Tab. 5).
A good correlation between both tests was found
(CI 95%,  r=0.87) (Fig. 3). There were distinctive
clusters of positive and negative results.
Discussion
Conductivity
Conductivity method provides a very high capacity to
identify  CF and  non-CF [6]. There are two systems
for sweat conductivity measurements.
The Macroduct system, which collects sweat into
capillary tubing, developed to limit sweat volume
loss from evaporation. Allied to conductivity meas-
urements, sweat analysis can be performed on
aliquots as small as 5 µl, on a minimum acceptable
sample of 15 µl collected over 30 minutes. The col-
lection of pure liquid sweat facilitates the measure-
ments of  conductivity, although it is also possible to
measure chloride on the sample collected through a
capillary system [11]. Studies proving good correla-
tion between chloride concentration and conductivi-
ty on the same sample of sweat have been performed
[6].
The Macroduct system has been further developed
to perform sweat collection and analysis in infants;
Nanoduct provides measurements of conductivity on
samples as small as 3 µl. However, unique continu-
ous flow analysis eliminates a separate collection
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Table 1. Sweat conductivity (Nanoduct) and chloride titration (quantitative pilocarpine iontophoresis) in 3 main groups
N – number of tests, Med. – median
Table 2. Sweat conductivity (Nanoduct) and chloride titration (quantitative pilocarpine iontophoresis)   in subgroups
N – number of tests; Med. – median; CF  – children with pancreatic sufficiency (CF/PS) and pancreatic insufficiency (CF/PI); Healthy – healthy  infants
from CF NBS recall (false positives); Control – healthy infants with negative screening test
phase and the performance of two different methods
on the same sample of sweat is no more possible.
Indeed, the Nanoduct system is more adapted for
infants which is why we use  it in our screening proce-
dure, although in our pilot CF NBS in the years  1999-
2003 we were working on Macroduct [1].
Although the producer recommends the same refer-
ence values for both systems (Macroduct and Nanod-
uct: 0 to 60 mmol/L are in the normal range; 60 to 80
mmol/L are borderline; and readings above 80 mmol/L
should be considered abnormal) discussing the results
of different studies the system used is always men-
tioned [7].
In Lezana study (Macroduct) on mixed age group,
results were as follow: conductivity ≥90 mmol/L con-
firmatory, value <75 mmol/l negative, values 75-89
mmol/L corresponded to the equivocal range [6].
According to our data it could not be applied for
infants.
Barben`s group [12] working on Nanoduct in the
mixed age group found 59 mmol/L as an upper limit of
normal conductivity, so also higher than our infants
data (50 mmol/L). He reported median conductivity
for  CF 115 mmol/l, non-CF 37 mmol/L, while in our
infant population the values were slightly lower: CF
105,5 mmol/L,  non-CF 28 mmol/L.
Median value of 24 mmol/L in healthy infants for
the Macroduct test was found by the Liverpool group
[13]. They performed both tests in 5-6 week old
healthy infants. They reported excellent limits of
agreement between the two methods. They showed
that conductivity is as valid as QPIT in the age group
5-6 wk and that chloride greater than 30 mmo/L should
be assessed in a specialist CF Centre.
According to the Cystic Fibrosis Foundation (CFF)
a patient having a conductivity result ≥50 mmol/L
should be referred for QPIT sweat chloride analysis
[10]. The manufacturer of the Sweat-Chek  (Wescor)
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Fig. 1. Receiver operating characteristics curve for conductivity
sweat  test showing the capacity to predict cystic fibrosis diagno-
sis (based on molecular analysis and clinical examination). Each
filled square represents the cut-off value starting from 50 (lower
left corner) to 61 (upper right corner).
Fig. 2. Receiver operating characteristics curve for chloride titra-
tion sweat  test showing the capacity to predict cystic fibrosis diag-
nosis (based on molecular analysis and clinical examination). Each
filled square represents the cut-off value starting from 34 (lower
left corner) to 47 (upper right corner).
Fig. 3. Correlation between sweat tests results obtained with the
conductivity method (Nanoduct) and chloride titration (Ion-
tophoresis); N=522, r=0.87, CI 95%. N – number of tests.  r – cor-
relation coefficient. CI – confidence interval.
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Table 3. Data for receiver operating characteristics curve for conductivity sweat  test (Cut-off = the concentration of NaCl in mmol/L. TP
= the number of true positive. FN = the number of false negative. FP = the number of false positive. TN = the number of true negative.
PPV=positive predictive  value. NPV=negative predictive value and kappa coefficient)
Table 4. Data for receiver operating characteristics curve for chloride titration sweat (Cut-off = the concentration of Cl- in mmol/L. TP =
the number of true positive. FN = the number of false negative. FP = the number of false positive. TN = the number of true negative.
PPV=positive predictive  value. NPV=negative predictive value and kappa coefficient)
recommends that conductivity results <60 mmol/L are
normal, >80 mmol/L are positive for CF, 60 to 80
mmol/L are borderline [7]. Lezana suggested even nar-
rower values for the conductivity method to diagnose
or exclude CF (90,75) [6].
Our infants values (Nanoduct) were: >60 mmol/L
confirmatory, value <50 mmol/l negative, values 50-60
mmol/L corresponded to the equivocal range (Tab. 5).
It proves, that as in the case of chloride concentration
values, conductivity values are also different in the
infant population.
Chloride concentration
Cut off values. A critical issue with regard to the
sweat test in infants is the choice of cut-off values. The
CFF consensus paper on the diagnosis of CF from
1998 supported the original Gibson and Cooke values,
with  a sweat chloride of >60 mmol/L to be diagnos-
tic, >40 mmol/L in infants up to the age of 3 months as
possible CF [10]. 
Those values, however, were found in CF NBS pro-
grammes not to be accurate in infants. Data from the
Victorian NBS [14] found infants with sweat chloride
in the 35-39 mmol/L range who had CF. An Aus-
tralasian consensus statement recommended the fol-
lowing values for sweat chloride in infants following
NBS: Cl ≥60 mmol/L – cystic fibrosis, Cl 30-59
mmol/L – borderline, Cl ≤29 –  normal [15]. Lowering
borderline cut-off to 30 mmol/L in infants following
screening was also supported by Farrell et al. [16].
They found the mean sweat chloride in healthy infants
to be 10.6±5.3 mmol/L. (95% CI, 9.9, 11.3) and in
F508del carriers 14.9±8.3 mmol/L (95% CI, 13.4,
16.4)
Sweat chloride of 30 mmol/L was 4 standard devi-
ations above healthy control infants and 2 standard
deviations above F508del carriers. There is not such a
difference between healthy controls and carriers in our
data. We did not find statistically significant differ-
ences between healthy infants with no mutations and
one mutation carriers.
Taking into consideration new data  on sweat chlo-
ride tests results in healthy and CF-affected infants
emerging from NBS programmes, the CFF consensus
from 2008 also updated  sweat reference ranges for
infants up to 6 months: ≤29mmol/L, CF unlikely; 30-
59 mmol/L, intermediate; ≥60 mmol/L, indicative of
CF [17]. 
In Mackay's data, the variation between the chlo-
ride concentration obtained from the two different
sides would suggest that, had only one side been test-
ed, that up to 13 patients (4.4% of total group, 48% of
those with at least one intermediate value) could be
classified differently [18]. We agree that comparable
results from sweat collected from two sites simultane-
ously permits improved confidence and is a useful
internal quality control procedure, even more so, when
two different methods are applied.
Observational group. An example of the complexity
of mutation analysis is found in the evolving picture of
individuals who are compound heterozygotes for CF-
causing mutation and the R117H mutation in the
CFTR gene. The likelihood of CF in this group is driv-
en by the length of a polythymidine tract in intron 8 of
the R117H allele. The presence of the 5 T tract in the
R117H background is usually associated with CF,
whereas  R117H(7T) is more often associated with iso-
lated male infertility or pancreatitis [19]. But individu-
als from both groups may display sweat chloride val-
ues in the normal, intermediate or diagnostic range and
some individuals with R117H(7T)  may present with
CF lung disease. Thus R117H(7T) is a mutation that
when present in trans with a CF-causing mutation can
cause a variable phenotype, ranging from normal to
CF. Still unknown diagnosis was the reason to assess
our analysed infants with R117H(7T) as an observa-
tional group. There are ongoing discussions whether
the R117H  variant should be included in CFTR muta-
tion panels [20].
Borderline sweat tests. Infants with borderline sweat
tests (Cl 34-46 mmol/L and Nanoduct 50-60 mmol/L)
after  CF NBS pose a difficult problem as not  all will
turn out to have CF. These children should be seen by
a physician experienced with CF, the sweat test should
be repeated at least twice on separate days. An extend-
ed mutation analysis should be performed. 
Some CFTR mutations which are clearly "CF caus-
ing" (in particular, 3849+10kb C>T) are associated
with normal or equivocal sweat electrolytes values.
Close liaison with local molecular genetics is needed
to determine these infants and to eventually include
these mutations in CF NBS mutation panel [21,22].
Chest radiography, stool examination (faecal elas-
tase), blood for electrolytes, albumin, liver function,
fat-soluble vitamins may add to the clinical picture.
We also recommend  repeat assessment at 3-6 months
of age (including another sweat test). We recognize
that it is possible that some of these infants may not
363Sweat tests and cystic fibrosis newborn screening protocol
©Polish Histochemical et Cytochemical Society
Folia Histochem Cytobiol. 2010:48(3): 363 (358-365) 
10.2478/v10042-010-0044-9
Table 5. Suggested normal values for sweat tests
have clinical evidence of CF for many years. "Miss-
ing" these  infants on NBS is an acceptable limitation
of the programme that is by nature a screening pro-
gramme 
Conductivity versus chloride concentration
Our study confirms the results from previous studies,
that  conductivity is reliable diagnostic analytical pro-
cedure for CF [2,6].
Until now the conductivity method has not been
accepted by the CFF or the National Committee for
Clinical Laboratory Standards (NCCLS) as a defini-
tive method for the disease [5], in spite of good agree-
ment between conductivity and chloride titration
found in several studies [6,8,13]. However, the meth-
ods used to assess conductivity as diagnostic tool
(ROC curve, sensitivity, specificity, predictive values,
kappa) clearly indicated also in our study that the con-
ductivity method has an excellent capacity (certainly
not worse than QPI) to discriminate between CF and
non-CF subjects. We agree with the other studies, that
conductivity might be as reliable as Quantitative chlo-
ride analysis to diagnose or exclude CF [6,12].
Patients with equivocal values of conductivity had also
equivocal QPIT values.
To our knowledge our work is the first to assess
bilateral use of different sweat tests as a part of routine
CF NBS protocol.
Conclusions
Because of the excellent capacity to discriminate
between CF and non-CF subjects Nanoduct is a very
useful tool in CF NBS protocol, allowing more time-
efficient organization of the diagnostic and training
procedures. 
The new analyzing system is quick, simple and reli-
able  and could be used as a diagnostic test in addition
to screening.
It has a failure rate comparable to other sweat tests
and could be used as a simple bedside test to confirm,
exclude or suspect CF. In cases with borderline values
other additional methods are indicated. The positive
result should be always confirmed with another sweat
test.
Simultaneous bilateral sweat testing with two dif-
ferent methods (concentration and conductivity) pro-
vides  an extra quality control system.
We hope that our study provides some evidence
based answer to the usefulness of conductivity relative
to chloride results in real patients, coupled to CFTR
mutation analysis in the context of developing world
wide screening programmes.
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